ALLR Q1 EPS Increased by Ascendiant Capital Markets

Allarity Therapeutics, Inc. (NASDAQ:ALLR) – Stock analysts at Ascendiant Capital Markets raised their Q1 2026 earnings per share (EPS) estimates for Allarity Therapeutics in a research note issued on Thursday, April 9th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.22) per share for the quarter, up from their prior forecast of ($0.24). Ascendiant Capital Markets has a “Buy” rating and a $9.75 price objective on the stock. The consensus estimate for Allarity Therapeutics’ current full-year earnings is ($78.08) per share. Ascendiant Capital Markets also issued estimates for Allarity Therapeutics’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.96) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Allarity Therapeutics has an average rating of “Hold” and a consensus price target of $9.75.

Allarity Therapeutics Price Performance

Shares of NASDAQ:ALLR opened at $1.19 on Wednesday. The business’s fifty day moving average price is $1.07 and its two-hundred day moving average price is $1.18. Allarity Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $2.35. The stock has a market capitalization of $18.83 million, a price-to-earnings ratio of -1.49 and a beta of 0.01.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.

Institutional Trading of Allarity Therapeutics

Several large investors have recently made changes to their positions in ALLR. Geode Capital Management LLC grew its holdings in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Allarity Therapeutics during the second quarter worth $51,000. Jane Street Group LLC bought a new stake in shares of Allarity Therapeutics during the second quarter worth $27,000. Private Advisor Group LLC bought a new position in Allarity Therapeutics in the third quarter valued at about $441,000. Finally, Citadel Advisors LLC bought a new position in Allarity Therapeutics in the third quarter valued at about $149,000. Institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics News Summary

Here are the key news stories impacting Allarity Therapeutics this week:

• Positive Sentiment: Ascendiant reiterated a Buy rating and maintained a $9.75 price target, which is materially higher than the current market price and may support upside interest from investors. Ascendiant report / MarketBeat
• Positive Sentiment: Ascendiant raised its Q1 2026 EPS estimate to ($0.22) from ($0.24) and nudged FY2026 to ($0.96) from ($0.97), modestly improving near-term and full-year loss expectations. Ascendiant report / MarketBeat
• Neutral Sentiment: Ascendiant issued stable 2027 quarterly and full‑year EPS projections (Q1–Q4 2027: ($0.24) each; FY2027: ($0.97)), providing a consistent forward view but little new catalyst. Ascendiant report / MarketBeat
• Negative Sentiment: Ascendiant trimmed Q2, Q3 and Q4 2026 EPS forecasts slightly (from ($0.24) to ($0.25) in most cases) — a modest deterioration that could weigh on sentiment, though the changes are very small in absolute terms. Ascendiant report / MarketBeat
• Negative Sentiment: Consensus figures cited alongside Ascendiant’s note (a listed current full‑year consensus of ($78.08) per share) are dramatically different from Ascendiant’s ~($0.96) FY view, creating data/expectations confusion that can increase volatility and investor uncertainty. Ascendiant report / MarketBeat

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.